This page shows you your search results in order of date.
Order by Relevance | Date
Total 15 results found since Jan 2013.
Delayed hypercoagulable state in COVID ‐19 adolescent patient: a case report
We report a case of an adolescent patient with mild symptoms of coronavirus disease 2019 (COVID-19) who was already in recovery state, but suddenly experienced hypercoagulable state and stroke-like symptoms. AbstractCoronavirus disease 2019 (COVID-19) is a systemic hyperinflammation disease which can cause severe respiratory symptoms and extrapulmonary manifestations. Hypercoagulable state in COVID-19 adolescent patient is a rare case. We present the case of a 16-year-old Indonesian boy with mild COVID-19 symptoms. Initially, the patient was treated with azithromycin, N-acetyl cysteine, etc. After several days of the treat...
Source: Respirology Case Reports - June 9, 2021 Category: Respiratory Medicine Authors: Desdiani Desdiani, Nita Yulianti, Anindita Basuki Tags: Case Report Source Type: research
Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.PMID:33898022 | PMC:PMC8053362 | DOI:10.1016/j.amsu.2021.102309
Source: Annals of Medicine - April 26, 2021 Category: Internal Medicine Authors: Abdelilah El Rhalete Inas Rhazi Amine Bensaid Ikram Zaid Houssam Bkiyer Nabila Ismaili Nouha Elouafi Brahim Housni Source Type: research
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - September 22, 2020 Category: Drugs & Pharmacology Authors: Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD Tags: Acta Pharmacol Sin Source Type: research
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
DISCUSSION: There is no convincing clinical evidence of chloroquine, hydroxychloroquine with or without azithromycin, and remdesivir use in COVID-19. As evidence of systemic inflammation is rapidly unfolding, there is a dire need to maximize our resources to find the best possible solutions to the current crisis while conclusive evidence from clinical trials emerges. PMID: 32691699 [PubMed - as supplied by publisher]
Source: Vascular - July 20, 2020 Category: Surgery Authors: Sultan S, Acharya Y Tags: Vascular Source Type: research
Study: Azithromycin doubles risk for cardiovascular death versus amoxicillin
People who take the commonly prescribed antibiotic azithromycin were nearly twice as likely to die from a heart attack, stroke or other cardiovascular event than users of amoxicillin, a study found.
Source: Health News - UPI.com - June 18, 2020 Category: Consumer Health News Source Type: news
What Causes Facial Nerve Palsy?
Discussion Facial nerve palsy has been known for centuries, but in 1821 unilateral facial nerve paralysis was described by Sir Charles Bell. Bell’s palsy (BP) is a unilateral, acute facial paralysis that is clinically diagnosed after other etiologies have been excluded by appropriate history, physical examination and/or laboratory testing or imaging. Symptoms include abnormal movement of facial nerve. It can be associated with changes in facial sensation, hearing, taste or excessive tearing. The right and left sides are equally affected but bilateral BP is rare (0.3%). Paralysis can be complete or incomplete at prese...
Source: PediatricEducation.org - June 3, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Poly(ADP-ribose)polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice.
Abstract Repurposing azithromycin has recently emerged as a promising strategy for the acute treatment of ischemic stroke. The mechanism of neuroprotection depends on the ability of this macrolide to promote polarization of microglia/macrophages towards beneficial M2 phenotypes. The immunomodulatory and anti-inflammatory effects of azithromycin, well documented in chronic inflammatory airway diseases, have been ascribed to the inhibition of the transcription factors nuclear factor (NF)-κB and activator protein (AP)-1. Since these inflammatory transcription factors are positively regulated by poly(ADP-ribose)polym...
Source: European Journal of Pharmacology - September 19, 2016 Category: Drugs & Pharmacology Authors: Petrelli F, Muzzi M, Chiarugi A, Bagetta G, Amantea D Tags: Eur J Pharmacol Source Type: research
Lyme Neuroborreliosis: A Potentially Preventable Cause of Stroke
A 15-year-old boy presented with multiple cranial nerve palsies including bilateral facial nerve palsy, right-sided limb weakness, and cerebellar signs. Nine months previously, after a trip to the Scottish Highlands where he reported a discrete scalp rash, he began experiencing lethargy, anorexia, arthromyalgia, and headache. He attended his general practitioner 4 months into the course of this illness and was treated with a short course of oral azithromycin, following which symptoms transiently improved.
Source: The Journal of Pediatrics - January 6, 2016 Category: Pediatrics Authors: Nicholas M. Allen, Heinz Jungbluth Tags: Insights and Images Source Type: research
Drug repurposing for immune modulation in acute ischemic stroke.
Abstract Innate immune cells play a dualistic role in the evolution of ischemic brain damage, with classic phenotypes promoting injury, and alternatively activated M2 microglia/macrophages or N2 neutrophils providing tissue remodelling and repair. Recently, a number of drugs commonly used for other indications (i.e., azithromycin, minocycline, bexarotene, rosiglitazone, metformin) was reported to provide neuroprotection in preclinical stroke models by promoting immune polarization towards non-inflammatory, protective phenotypes. Repurposing drugs with a well-established safety profile should allow a reduction in t...
Source: Current Opinion in Pharmacology - December 1, 2015 Category: Drugs & Pharmacology Authors: Amantea D, Bagetta G Tags: Curr Opin Pharmacol Source Type: research
Azithromycin protects mice against ischemic stroke injury by promoting macrophage transition towards M2 phenotype.
Abstract To develop novel and effective treatments for ischemic stroke, we investigated the neuroprotective effects of the macrolide antibiotic azithromycin in a mouse model system of transient middle cerebral artery occlusion. Intraperitoneal administration of azithromycin significantly reduced blood-brain barrier damage and cerebral infiltration of myeloid cells, including neutrophils and inflammatory macrophages. These effects resulted in a dose-dependent reduction of cerebral ischemic damage, and in a remarkable amelioration of neurological deficits up to 7days after the insult. Neuroprotection was associated ...
Source: Experimental Neurology - October 27, 2015 Category: Neurology Authors: Amantea D, Certo M, Petrelli F, Tassorelli C, Micieli G, Corasaniti MT, Puccetti P, Fallarino F, Bagetta G Tags: Exp Neurol Source Type: research
Azithromycin is not associated with QT prolongation in hospitalized patients with community‐acquired pneumonia
ConclusionsAzithromycin treatment was not associated with QT prolongation in patients with severe CAP. Nonetheless, in a large majority of hospitalized CAP patients, QT prolongation and pathological QTc develop regardless of the antibiotic used, especially in patients with previous stroke or a higher pneumonia score. Copyright © 2015 John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - August 2, 2015 Category: Drugs & Pharmacology Authors: Lee Hilary Goldstein, Ahmad Gabin, Abdallah Fawaz, Nahum Adam Freedberg, Naama Schwartz, Mazen Elias, Walid Saliba Tags: Original Report Source Type: research
Mycoplasma pneumoniae infection presenting as stroke and meningoencephalitis with aortic and subclavian aneurysms without pulmonary involvement- a rare case report (P5.122)
Conclusion Mycoplasma infection should be considered in patients presenting with fever, aseptic meningitis and stoke even in absence of respiratory symptoms. Early detection and treatment with appropriate antibiotics offers excellent outcome.Disclosure: Dr. Inshasi has nothing to disclose. Dr. Sarathchandran has nothing to disclose. Dr. Almadani has nothing to disclose. Dr. Alrukn has nothing to disclose. Dr. Alboudi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Inshasi, J., Sarathchandran, P., Almadani, A., Alrukn, S., Alboudi, A. Tags: Ischemia, Myelitis, and Vascular Malformations Source Type: research
Highlights from this issue
June Issue BJO Temporary monocular blindness is a risk factor for stroke and may need quick surgical therapy. The highest risk period for suffering a stroke after a temporary monocular blindness or amaurosis fugax is the first 14 days after the event, and this is the recommended threshold for performing carotid endarterectomy. Naylor and colleagues stress the importance of referring ophthalmological patients presenting with transient monocular blindness (or blindness felt to be "monocular") to stroke units for further diagnosis and therapy of a potential carotid artery stenosis.1 Purulent Conjunctivitis I Children In an in...
Source: British Journal of Ophthalmology - May 17, 2014 Category: Opthalmology Authors: Barton, K., Chodosh, J., Jonas, J. B. Tags: At a glance Source Type: research